QBK249 G
Alternative Names: QBK 249 GLatest Information Update: 19 Aug 2024
At a glance
- Originator Quadira Biosciences
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical HER2 positive breast cancer
Most Recent Events
- 30 Jul 2024 Preclinical trials in HER2-positive-breast-cancer in Switzerland (Parenteral) prior to July 2024 (Quadira Biosciences pipeline, July 2024)
- 30 Jul 2024 Adverse events and pharmacodynamics data from a preclinical studies in HER2 positive breast cancer released by Quadira Biosciences (Quadira Biosciences website, July 2024)